CTSU E1609. A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
Esther Rehmus, MD
McDowell Cancer Research at 330-344-6348
Akron General Medical Center 400 Wabash Avenue Akron, OH 44307 330-344-6000 1-800-221-4601 © 2013 Akron General Health System
This site complies with the HONcode standard for trustworthy health information: verify here.